

Scaling Manufacturing of Critical Protein Medicines with ALiCE®

LenioBio secured a €3.7 million EU4Health grant to advance ALiCE®, our proprietary cell-free protein expression system, as a rapid and on-demand manufacturing technology for protein-based medicines.

This action grant comes from the European Commission's Health Emergency Preparedness and Response Authority (HERA), with the aim to improve European resilience when faced with crises.

LenioBio is proud to contribute to this mission with ALiCE® and to further the cell-free biomanufacturing field.

Key Goals of the Project



Continued scaling
of ALiCE® lysate
production



Expand ALiCE®
for **key protein**
medicines



Prepare for **GMP-**
grade production



Explore the **details** in our
press release



LenioBio | Erkrather Str. 40 | 40231 Düsseldorf | sales@leniobio.com



InnoManContiMod PROJECT

**Innovative Protein Medicine Biomanufacturing
with Continuous-Modular**

An EU4Health-Funded Project



**Co-funded by
the European Union**

"Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them."